Multilaminate ECM Graft for Staged Growth Factor Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tissue graft devices are inadequate for effectively treating chronic wounds due to prolonged wound healing processes, which compromise the skin's ability to defend against infections and lead to complications such as amputation, as they fail to provide differential treatment and optimal growth factor delivery during the healing process.
Innovation Solution
A multilaminate medical graft product comprising two layers of remodelable extracellular matrix tissue material, where one layer is enriched with a growth factor like TGF-beta relative to the other, allowing for differential tissue repair and enhanced wound healing by varying growth factor delivery during the healing process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If a single-layer graft material is used, then the device complexity is low, but the ability to provide differential treatment and optimal growth factor delivery during different healing stages is insufficient
Solution Approach 1:
The graft material is divided into multiple layers, with each layer containing different concentrations of growth factors tailored to specific healing phases. This segmentation allows differential treatment of chronic wounds by delivering appropriate growth factor concentrations at different depths and stages of healing, resolving the contradiction between adaptability and complexity.
Solution Approach 2:
Different layers of the graft material are engineered with distinct local properties, specifically varying growth factor concentrations (e.g., TGF-beta, FGF-2, PDGF) in each layer. This local quality differentiation enables targeted delivery of bioactive components to match the specific needs of different healing stages, improving adaptability while maintaining a manageable multilayer structure.
2Productivity
If uniform growth factor distribution is used throughout the graft, then the manufacturing process is simple, but the wound healing process cannot be optimized across different healing stages
Solution Approach 1:
The manufacturing process is segmented into steps for creating multiple layers with different growth factor concentrations. Each layer can be prepared separately with specific bioactive component levels, then assembled into the final multilayer graft. This segmented approach optimizes wound healing efficiency by providing stage-appropriate growth factor delivery while keeping manufacturing complexity manageable through modular preparation.
Solution Approach 2:
The concentration of growth factors is varied as a key parameter across different layers of the graft material. By changing the concentration parameter from layer to layer (e.g., high TGF-beta in early-healing layers, lower concentrations in later-stage layers), the manufacturing process achieves optimized wound healing efficiency across different healing stages while maintaining controlled complexity through systematic parameter variation.
3Reliability
If high growth factor concentration is delivered throughout the entire healing process, then early wound healing is promoted, but later stages receive excessive growth factors that may cause complications
Solution Approach 1:
The graft material is segmented into layers with progressively decreasing growth factor concentrations from the layer contacting the wound to the outer layers. This segmentation ensures reliable control of the healing process by delivering high growth factor concentrations only where and when needed (early stages at the wound interface), while outer layers provide lower concentrations for later stages, avoiding complications from excessive growth factor delivery.
Solution Approach 2:
Each layer of the graft material is engineered with specific local quality characteristics, including tailored growth factor concentrations matched to the healing stage it addresses. The layer in direct contact with the wound contains the highest concentration of growth factors for immediate healing promotion, while subsequent layers contain progressively lower concentrations, providing reliable healing process control without the device complexity of a fully homogeneous structure.
Data Source
Figure 1
Figure 2
AI summary
Described, in certain aspects of the invention, are multilaminate medical graft products, as well as methods for preparing and using the same. An illustrative multilaminate medical graft product of the invention comprises a first layer of remodelable extracellular matrix (ECM) material bonded to a second layer of remodelable ECM material, wherein the first material layer is enriched with a growth factor relative to the second material layer. Such a remodelable ECM material may be comprised of submucosa from a warm-blooded vertebrate, for example, porcine small intestinal submucosa (SIS).